非肝硬化门静脉系统血栓形成临床管理

doi:10.3969/j.issn.1672-5069.2024.01.003

实用肝脏病杂志 ›› 2024, Vol. 27 ›› Issue (1): 7-10.doi: 10.3969/j.issn.1672-5069.2024.01.003

非肝硬化门静脉系统血栓形成临床管理

鲁文婷, 张峰

210008 南京市南京大学医学院附属鼓楼医院消化内科

收稿日期:2023-10-26 出版日期:2024-01-10 发布日期:2024-01-04
通讯作者: 张峰,E-mail:fzdndx@126.com
作者简介:鲁文婷,女,25岁,硕士研究生。E-mail:luwenting9858@outlook.com

Clinical management of patients with non-cirrhotic portal veinthrombosis

Lu Wenting, Zhang Feng

Department of Gastroenterology, DrumTower Hospital, Affiliated to Nanjing University Medical School, Nanjing 210008, Jiangsu Province, China

Received:2023-10-26 Online:2024-01-10 Published:2024-01-04

摘要/Abstract

关键词: 非肝硬化门静脉系统血栓形成, 病因, 诊断, 治疗

Key words: Non-cirrhosis portal venous thrombosis, Etiology, Diagnosis, Treatment

鲁文婷, 张峰. 非肝硬化门静脉系统血栓形成临床管理[J]. 实用肝脏病杂志, 2024, 27(1): 7-10.

Lu Wenting, Zhang Feng. Clinical management of patients with non-cirrhotic portal veinthrombosis[J]. Journal of Practical Hepatology, 2024, 27(1): 7-10.

[1] Rajani R, Bjornsson E, Bergquist A, et al. The epidemiology and clinical features of portal vein thrombosis: a multicentre study. Aliment Pharmacol Ther, 2010,32(9):1154-1162.
[2] Hernández-Gea V, De Gottardi A, Leebeek FWG, et al. Current knowledge in patho-physiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral s-planchnic vein thrombosis. J Hepatol, 2019,71(1):175-199.
[3] Garcia-Pagán JC, Hernández-Guerra M, Bosch J. Extrahepatic portal vein thrombosis.Semin Liver Dis, 2008,28(03):282-292.
[4] Spaander VM, van Buuren HR, Janssen HL. The management of non-cirrhotic non-malignant portal vein thrombosis and concurrent portal hypertension in adults. Aliment Pharmacol Ther, 2007,26(s2):203-209.
[5] Iba T, Levy JH. Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. J Thromb Haemost, 2018,16(2):231-241.
[6] Falanga A, Russo L, Milesi V, et al. Mechanisms and risk factors of thrombosis in cancer. Crit Rev Oncol Hematol, 2017,118:79-83.
[7] Stegner D, Dütting S, Nieswandt B. Mechanistic explanation for platelet contribution to cancer metastasis. Thromb Res, 2014,133:S149-S157.
[8] Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood, 2022,140(11):1200-1228.
[9] Elkrief L, Payancé A, Plessier A, et al. Management of splanchnic vein thrombosis. JHEP Rep, 2023,5(4):100667.
[10] Kiladjian JJ, Cassinat B. Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies. Am J Hematol, 2023,98(5):794-800.
[11] Moliterno AR, Kaizer H. Applied genomics in MPN presentation. Hematology Am Soc Hematol Educ Program, 2020,2020(1):434-439.
[12] de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII – Renewing consensus in portal hypertension. J Hepatol, 2022,76(4):959-974.
[13] Bureau C, Laurent J, Robic MA, et al. Central obesity is associated with non-cirrhotic portal vein thrombosis. J Hepatol, 2016,64(2):427-432.
[14] Fontana L, Eagon JC, Trujillo ME, et al. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes, 2007,56(4):1010-1013.
[15] Mamad H, Benkirane S, El Aissaoui Y, et al. Prothrombotic disorders in non-cirrhotic, non-tumoral portal vein thrombosis. Thromb Res, 2021,203:152-154.
[16] De Broucker C, Plessier A, Ollivier-Hourmand I, et al. Multicenter study on recent p-ortal venous system thrombosis associated with cytomegalovirus disease. J Hepatol, 2022,76(1):115-122.
[17] Plessier A, Darwish-Murad S, Hernandez-Guerra M, et al. Acute portal vein thrombo-sis unrelated to cirrhosis: A prospective multicenter follow-up study. Hepatology, 2010,51(1):210-218.
[18] Llop E, Seijo S. Actuación ante la trombosis portal no cirrótica no tumoral. Gastroenterol Hepatol, 2016,39(6):403-410.
[19] Noronha Ferreira C, Seijo S, Plessier A, et al. Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis. Hepatology, 2016,63(5):1640-1650.
[20] Northup PG, Garcia-Pagan JC, Garcia-Tsao G, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 2021,73(1):366-413.
[21] Bettiol A, Alibaz-Oner F, Direskeneli H, et al. Vascular Behçet syndrome: from pathogenesis to treatment. Nat Rev Rheumatol, 2023,19(2):111-126.
[22] Sicre de Fontbrune F, Peffault de Latour R. Ten years of clinical experience with eculizumab in patients with paroxysmal mocturnal hemoglobinuria. Semin Hematol, 2018,55(3):124-129.
[23] Baiges A, Procopet B, Silva-Junior G, et al. Incidence and factors predictive of recurrent thrombosis in people with non-cirrhotic portal vein thrombosis. J Hepatol, 2023,78(1):114-122.
[24] Naymagon L, Tremblay D, Schiano T, et al. The role of anticoagulation in pylephle-bitis: a retrospective examination of characteristics and outcomes. J Thromb Thrombo-lysis, 2020,49(2):325-331.
[25] Burnett AE, Mahan CE, Vazquez SR, et al. Guidance for the practical management o-f the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis, 2016,41(1):206-232.
[26] Naymagon L, Tremblay D, Zubizarreta N, et al. The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis. Blood Adv, 2020,4(4):655-666.
[27] Mansour N, Öcal O, Gerwing M, et al. Interventional recanalization therapy in patients with non-cirrhotic, non-malignant portal vein thrombosis: comparison between transjugular versus transhepatic access. Abdom Radiol (NY), 2022,47(3):1177-1186.

非肝硬化门静脉系统血栓形成临床管理

Clinical management of patients with non-cirrhotic portal veinthrombosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈从新, 陈曦, 王莉苹, 赵秋香, 刘颖, 周海洋. 糖皮质激素在肝病治疗中的应用[J]. 实用肝脏病杂志, 2024, 27(3): 321-323.
[2]	赵玉雯, 朱传龙. 肝硬化营养不良及肌少症治疗研究进展[J]. 实用肝脏病杂志, 2024, 27(3): 324-328.
[3]	虞珊珊, 张业婷, 王元鹏, 袁静文, 肖立. 慢性乙型肝炎患者血清MMP-1、MMP-2、TIMP-1和HIF-1α变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(3): 329-332.
[4]	罗良德, 任成果, 王守军, 邓颖春. 恩替卡韦联合多烯磷脂酰胆碱治疗慢性乙型肝炎合并NASH患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 333-336.
[5]	周安琪, 孟舒婷, 吴应冬, 张弦. 接受核苷(酸)类似物抗病毒的慢性乙型肝炎患者发生低病毒血症危险因素分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 337-340.
[6]	彭玉静, 郭航, 陈俊光. 应用超声评分联合STE/STQ定量检测肝脏硬度评估慢性乙型肝炎患者肝纤维化程度价值研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 345-348.
[7]	程艳洁, 王鹏飞, 李峻. 水飞蓟素联合复方蛋氨酸胆碱治疗酒精性肝炎患者疗效及其对血清肝纤维化指标的影响^*[J]. 实用肝脏病杂志, 2024, 27(3): 349-352.
[8]	曹焱芬, 邹昊轩, 谢艳. 体检人群血浆致动脉粥样硬化指数诊断代谢相关脂肪性肝病效能分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 361-365.
[9]	徐秋萍, 黄彬, 陈敏, 余静. 泼尼松与泼尼松联合硫唑嘌呤治疗自身免疫性肝炎患者外周血MDSCs百分比、肝组织白细胞介素-35和血清CD38水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(3): 374-377.
[10]	姜正伟, 周冰清, 汤洁, 蒋蓓莉. 血清抗糖蛋白210抗体阳性的原发性胆汁性胆管炎患者临床特征分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 378-381.
[11]	高萍, 高学松, 张亦瑾, 孙磊, 刘楠, 李洪杰, 刘亚平, 高丽丽, 段雪飞. 8例血色病患者临床与基因突变特征分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 386-389.
[12]	董旭, 秦阳华, 陈怡, 许明晓, 葛玲玲, 徐圣, 廖威. 预后营养指数联合全身免疫炎症指数评估乙型肝炎相关慢加急性肝衰竭患者预后临床价值研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 390-393.
[13]	李菊兰, 张华堂, 郑怡娟, 余雪平, 邓勇, 苏智军. 恩替卡韦联合扶正化瘀片治疗乙型肝炎肝硬化患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 402-405.
[14]	蔡峻岭, 苏立, 郝丽, 赵敏, 裴旭东. 基于索磷布韦的直接抗病毒药物治疗丙型肝炎肝硬化患者疗效评价^*[J]. 实用肝脏病杂志, 2024, 27(3): 406-409.
[15]	白萍, 王汉, 刘芮, 曾智萍. 多层螺旋CT与磁共振LAVA增强扫描诊断肝内占位性病变性质效能分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 422-425.